Pink Sheet is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


Xarelto Back On Track: J&J Answers "Complete Response" Letter And Files For Atrial Fibrillation

This article was originally published in Pharmaceutical Approvals Monthly

Executive Summary

Johnson & Johnson and Bayer HealthCare may gain a market advantage if regulators grant an approval with indications for both chronic and acute use of its anticoagulant rivaroxaban, based on regulatory filings the co-development partners announced Jan. 5.

You may also be interested in...

Apixaban Study Halted – But It May Not Cause Much Damage To The Program

The Phase III APPRAISE-2 trial of Bristol-Myers Squibb/Pfizer’s apixaban in acute coronary syndrome has been terminated due to increased bleeding, on the recommendation of a data safety monitoring committee.

Bristol/Pfizer's Apixaban Gets A Chance At The Inside Track

FDA has agreed to review the anticoagulant based on the results of the AVERROES trial, offering a potentially faster route to market.

FDA Plays It Safe With Boehringer Ingelheim's Pradaxa By Approving A Single Dosing Option

Regulators accept bleeding risk for superiority over warfarin, staying away from a temptingly safer but less effective dabigatran dose.

Related Content


Latest News
See All



Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts